ADMA Biologics Inc (ADMA) News
Filter ADMA News Items
ADMA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ADMA News Highlights
- For ADMA, its 30 day story count is now at 3.
- Over the past 19 days, the trend for ADMA's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about ADMA are DOW and ROSE.
Latest ADMA News From Around the Web
Below are the latest news stories about ADMA BIOLOGICS INC that investors may wish to consider to help them evaluate ADMA as an investment opportunity.
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2022 Revenues and Provides 2023 Financial GuidanceFourth Quarter 2022 Preliminary Unaudited Total Revenues of Approximately $49-$50 Million, an 89% Year-Over-Year Increase Full Year 2022 Preliminary Unaudited Total Revenues of Approximately $153-$154 Million, an 90% Increase Over Full Year 2021 Full Year 2023 Total Revenues are Expected to be $210 Million or More, Representing Approximately 40% Year-Over-Year Growth Rate First-Time Positive EBITDA Expected During Second Half of 2023 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 17, 2023 (GLOBE NEWSWI |
12 Best Performing NASDAQ Stocks in 2022In this article, we discuss 12 best performing NASDAQ stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing NASDAQ Stocks in 2022. The S&P 500 rose 0.6% to 3,844.82 on December 23, while the Nasdaq Composite gained 0.2% to close at 10,497.86. The Dow Jones Industrial […] |
12 Best Performing Biotech Stocks in 2022In this article, we discuss 12 best performing biotech stocks in 2022. If you want to see more stocks in this selection, check out 5 Best Performing Biotech Stocks in 2022. Fitch Ratings has assigned a Neutral rating to the global pharmaceutical and biotech industry, which indicates the assumption of a collaborative operating backdrop in […] |
ADMA Biologics Announces FDA Approval for Room Temperature Storage of ASCENIV™ & BIVIGAM®FDA approvals for both ASCENIV and BIVIGAM provide for room temperature (25°C) storage conditions for up to 4 weeks during the first 24 months of the 36-month approved shelf life Provides for improved inventory management and ease of product administration to patients Approval for ambient storage conditions for ASCENIV & BIVIGAM is immediately effective and now commercially available to U.S. healthcare providers RAMSEY, N.J. and BOCA RATON, Fla., Dec. 13, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, |
Adam Grossman Is The Co-Founder of ADMA Biologics, Inc. (NASDAQ:ADMA) And They Just Picked Up 1.2% More SharesWhilst it may not be a huge deal, we thought it was good to see that the ADMA Biologics, Inc. ( NASDAQ:ADMA... |
ADMA Biologics Announces Closing of $69 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesRAMSEY, N.J. and BOCA RATON, Fla., Dec. 09, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, in addition to the exercise in full of the underwriters’ |
ADMA Biologics Announces Pricing of Public Offering for $60 Million of Common StockRAMSEY, N.J. and BOCA RATON, Fla., Dec. 07, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today priced its previously announced underwritten public offering of 20,979,020 shares of its common stock at a public offering price of $2.86 per share, resulting in gross proceeds of approximately $60 million before deducting |
ADMA Biologics Announces Proposed Public Offering of Common StockRAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 pe |
ADMA Biologics Announces Preliminary Fourth Quarter 2022 Revenue EstimateFourth Quarter 2022 Preliminary Estimated Total Revenues of Approximately $48-$50 MillionRAMSEY, N.J. and BOCA RATON, Fla., Dec. 06, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced preliminary estimates for its total revenue for the quarter- and year-ended December 31, 2022. Based on the most current in |
Top Penny StocksADMA Biologics, Borr Drilling, and Nordic American Tankers lead the momentum category by roughly doubling in the past year while the large-cap Russell 1000 fell 15% and the small-cap Russell 2000 lost almost a fifth of its value. |